University of Massachusetts, Amherst
Trial Pipeline
Effects of Aphasia Identification Cards on Service Workers' Comprehension of People With Aphasia
NCT06990997
Burning Mouth Syndrome: Symptoms and Management
NCT07016555
The Function of Biphasic Sleep in Infants
NCT06399939
Sleep-dependent Learning in Aging
NCT03840083
Feasibility and Fidelity of a Gross Motor-based Physical Activity Intervention on Cognition in Preschool-age Children
NCT05949866
Venous Thrombosis Prevention and Sleep Quality: A Comparison of the Kendall and the Recovery Health MAC Systems
NCT06042686
Family-centered Mental Health Promotion Intervention
NCT04453709
Voice Treatment for Parkinson's Disease
NCT03700684
Enhancing Mental Health Care by Scientifically Matching Patients to Providers' Strengths
NCT02990000
Lifestyle Intervention in Overweight and Obese Pregnant Hispanic Women
NCT01868230
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
What the Pipeline for University of Massachusetts, Amherst Shows
According to the ClinicalTrials.gov registry, University of Massachusetts, Amherst is linked to 37 US clinical trials across every stage of research activity. Of those, 31 studies are currently recruiting — about 84% of the sponsor's indexed portfolio — and 5 are already marked complete, representing roughly 14% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for University of Massachusetts, Amherst reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 1 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for University of Massachusetts, Amherst is Deep Venous Thrombosis of Deep Femoral Vein with 1 linked trial, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.